eXIthera CEO, Dr. Neil Hayward, is featured on the Cutting Edge Cast

eXIthera is doing big things with small molecules. This clinical-stage biotech company is developing therapies to maintain the balance between healthy blood flow and clotting, specifically during heart surgery. In today’s Cutting Edge Cast, eXIthera CEO Neil Hayward, Ph.D., explains why this therapy is critical for patients.

Cream of the clotbusters? eXIthera ‘teas’ off at AHA with strong Phase I data

eXIthera Pharmaceuticals Inc. CEO Neil Hayward told BioWorld he's hoping to build a "continuum of care" around factor XIa inhibitor EP-7041, after Phase I data showed the intravenous (I.V.) version of the antithrombotic safe and well-tolerated in healthy volunteers after single or multiple ascending intravenous doses – and even turned up some clues to efficacy.